The TROP-2 ADC demonstrates comparable efficacy to cisplatin in both in vivo and in vivo assays, indicating the potential of TROP-2 as a novel target for advanced PSCC patients. Here, TACSTD2 is linked to squamous cell carcinoma of penis.